ANAPAM 30 mg Price

Overview

Welcome to Dwaey, specifically on ANAPAM 30 mg Tablet/Film coated page.
This medicine contains an important and useful components, as it consists of Nefopam hydrochloride.
ANAPAM 30 mg is available in the market in concentration 30 mg/tablet and in the form of Tablet/Film coated.

KEY PHARMACEUTICALS LTD, is the producer of ANAPAM 30 mg and it is imported from UK, The most popular alternatives of ANAPAM 30 mg are listed downward .

Mode Of Action

Hydrochlorothiazide inhibits the reabsorption of Na and chloride in the distal tubules causing increased excretion of Na and water K and hydrogen ions. Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.

Indication

• Hypertension
• Diabetic nephropathy

Precaution

Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation. Lactation: discontinue drug or do not nurse

Side Effects

• 1-10% Olmesartan Dizziness (3%)
• Headache (1%)
• Fatigue
• Diarrhea (1%)
• Hyperglycemia (1%)
• Hypertriglyceridemia (1%)
• Back pain (1%)
• Bronchitis (1%)
• Flu-like symptoms (1%)
• Pharyngitis (1%)
• Rhinitis (1%)
• Sinusitis (1%)
• URI (1%) Frequency Not Defined Chest pain
• Peripheral edema
• Rash
• Hyperuricemia
• Dizziness
• Hyperlipidemia
• Diarrhea
• Hyperuricemia
• Hematuria
• Hyperglycemia
• Upper respiratory infections
• Increased transaminases
• Gastroenteritis
• Dyspepsia
• Arthralgia
• Arthritis
• Myalgia
• Back pain
• Increased CPK
• Hydrochlorothiazide
• Anorexia
• Epigastric distress
• Hypotension
• Orthostatic hypotension
• Photosensitivity
• Anaphylaxis
• Anemia
• Confusion
• Erythema multiforme
• Stevens-Johnson syndrome
• Exfoliative dermatitis including toxic epidermal necrolysis
• Dizziness
• Hypokalemia and/or hypomagnesemia
• Hyperuricemia
• Headache Potentially Fatal: Acute renal failure.

Contra indication

Hypersensitivity to olmesartan medoxomil, hydrochlorothiazide or to other sulfonamide-derived drugs. Severe hepatic & renal impairment (CrCl <30 mL/min); cholestasis & biliary obstructive disorders; refractory hypokalemia; hypercalcemia; hyponatraemia, symptomatic hyperuricaemia; anuria. Concomitant use w/ aliskiren in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m2). Pregnancy (2nd & 3rd trimester) & lactation.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters)